Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
It is Predicted that New Cancer Drug Tracker AP23573 Will Reach the Market in Early 2010
May 1st, 2007
Research and Markets has announced the addition of New Cancer Drug Tracker: AP23573 to their offering. Long gone are the days when a drug successfully completing Phase III trials was virtually assured of launch. The results of late-stage clinical trials are scrutinised as never before, and even products that surmount safety and efficacy requirements must overcome increasingly challenging pharmacoeconomic and medical outcome hurdles. The high cost of new cancer therapies has made them targets for critical analysis. The rewards may be great for patients and companies alike, but...
Source: Cancer Weekly (2007-05-01)
|
